No Longer Artificial – AI in Pharma and Healthcare AI firm Lantern Pharma has joined Genomics England’s ground-breaking 100,000 Genomes Project industry partnership to advance the role of AI in precision medicine.
Precision Oncology Company Lantern Pharma's Artificial Intelligence Approach NEW YORK--(BUSINESS WIRE)--Lantern Pharma is applying Artificial Intelligence (AI) to tailor multiple promising precision drug programs to the right cancer patients through use of their RADRTM platform (Response Algorithm for Drug Rescue and Positioning).
DALLAS--(BUSINESS WIRE)--Genomics England and Lantern Pharma, a clinical stage pharma company specializing in precision oncology using artificial intelligence, announced today that Lantern will join Genomics England’s Discovery Forum industry partnership. The partnership aims to translate groundbreaking research into innovative treatments, and ultimately patient benefit, as rapidly as possible.
When the Precision Medicine Initiative was announced by President Obama in 2015, he said: “delivering the right treatments, at the right time, every time, to the right person.” As the next heralded breakthrough in healthcare, simply put it is the ultra-tailored therapy.
Lantern Pharma: Precision Medicine Pioneers According to a recent study, the overall success rate for drugs moving through clinical trials to approval by the US Food and Drug Administration is only about 10%. Even though cancer is the most closely studied disease for drug development, oncology drugs have the toughest time making their [...]